STAMFORD, Conn.--Aug. 2, 2007--Delcath Systems, Inc. (Nasdaq:DCTH) today announced that its Chief Executive Officer, Richard L. Taney, will present at the upcoming Canaccord Adams Global Growth Conference, which connects small- to mid-cap companies with investors. The Delcath presentation is scheduled for 8:00 AM Eastern Time on Thursday, August 9, 2007. The event will be held at the InterContinental Boston from August 7 - 9, 2007.

Individuals may listen to a live webcast of the presentation by logging on to the Investors section of Delcath's web site, www.delcath.com, a few minutes prior to start time. The presentation will be archived for 90 days.

About Delcath Systems, Inc.
Delcath Systems is the developer of percutaneous perfusion technology for organ- or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath system is currently being tested with the drug melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website www.delcath.com.